## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `what-are-peptides-neuropathy`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `what-are-peptides-neuropathy` v2 · content_hash `e91f4665c0a8f907…` · thread_head genesis · 20 DIVs
- **thesis (c1):** Long-acting C-peptide improved vibration perception threshold by 25% versus placebo in a 52-week RCT of 250 type 1 diabetes patients with neuropathy, but did not improve nerve conduction velocity or clinical scores.
  - c2 [human/active] ARA290 increased corneal small nerve fiber density and reduced neuropathic symptom scores in placebo-controlled trials of patients with sarcoidosis-associated s
  - c3 [preclinical/active] BPC-157 promoted axon regeneration and functional recovery after sciatic nerve transection in rat models.
  - c4 [anecdotal/active] Reddit users report variable symptom relief with ARA290, including reduced burning and allodynia in some cases alongside occasional flares.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `what-are-peptides-neuropathy`
- **title:** What Are Peptides for Neuropathy
- **url:** https://miscsubjects.com/a/what-are-peptides-neuropathy
- **register:** source_ledger
- **updated:** 2026-07-17T02:43:33.466Z
- **tags:** peptide, matrix

## Body

## What's breaking down

Neuropathy involves progressive damage to peripheral nerves. Axons lose integrity. Myelin sheaths thin. Blood flow to nerves drops. Inflammatory signals stay elevated. The body's natural repair systems cannot keep pace with ongoing breakdown from diabetes, injury, inflammation, or other triggers. This imbalance leaves nerves hypersensitive or numb. Pain signals fire without clear cause. Sensation fades in a length-dependent pattern, often starting in the feet.

Repair pathways include growth factors that encourage axon regrowth. Anti-inflammatory signals that calm overactive immune cells in nerves. Structural proteins that rebuild nerve architecture. When these lag, symptoms persist. Peptides under study target specific steps in these pathways rather than only blocking pain signals.

## How these fit together

Different peptides address distinct layers of nerve degeneration. One activates a repair receptor that shifts inflamed tissue toward healing. Another shows axon regrowth signals in animal models of nerve cuts. A third improves vibration sense in people with diabetes-related nerve changes. These actions map onto separate parts of the breakdown: inflammation control, structural repair, and functional recovery. No single peptide covers every layer in current data.

## What the evidence actually shows

Human data centers on two compounds. A randomized double-blind trial gave long-acting C-peptide weekly for 52 weeks to 250 people with type 1 diabetes and mild to moderate peripheral neuropathy. Vibration perception threshold improved 25 percent versus almost no change on placebo. Nerve conduction velocity and clinical neuropathy scores showed no difference from placebo. (source from Diabetes Care 2016)

ARA290 received testing in small fiber neuropathy linked to sarcoidosis and type 2 diabetes. In placebo-controlled studies, patients reported lower neuropathic symptom scores and better quality of life after four weeks. Corneal confocal microscopy showed increased small nerve fiber density in one trial after 28 days. Skin biopsies did not show the same regrowth. Pain relief reached about 25-40 percent in some measures. (sources from Pain Reports 2016 and related PMC articles)

Preclinical work on BPC-157 used rat models of sciatic nerve transection and spinal cord injury. Treated rats showed faster functional recovery, thicker regenerating axons, and better organized nerve bundles under microscope. These studies count as animal evidence only. Human reports remain limited to one small retrospective knee pain series with no neuropathy-specific outcomes.

Semax studies in rats demonstrated reduced pain sensitivity and improved learning after intraperitoneal or intranasal dosing. Russian clinical use exists for stroke and encephalopathy, yet specific large neuropathy trials are absent from English-language records.

## What scientists say

Researchers describe ARA290 as reprogramming a damaging inflammatory environment into one that supports repair via the innate repair receptor. They note measurable symptom gains and early structural hints in cornea but call for larger trials. C-peptide investigators observed selective sensory improvement without broad electrophysiologic change and concluded further study is warranted. Animal researchers on BPC-157 highlight consistent nerve healing across trauma models yet stress the gap to human application.

## What people say on Reddit

Users in neuropathy and small fiber neuropathy forums discuss ARA290 most often. Several report symptom relief within hours to days at doses around 4 mg daily for weeks. Some note reduced allodynia and burning. Others describe pins-and-needles flares that led them to stop. Cost and sourcing concerns appear repeatedly. A few mention combining with other approaches. BPC-157 threads focus more on general healing claims than documented neuropathy outcomes. Experiences remain anecdotal and vary widely.

## What people say on X

Public posts on X about peptides for neuropathy stay sparse compared with Reddit. Occasional mentions link ARA290 to nerve repair discussions, often referencing the same human trials. Users rarely share personal outcome details in searchable posts. Broader peptide conversations emphasize research status over personal results.

## What we do not know

Large phase III trials confirming long-term nerve regrowth or durable symptom control are missing for most compounds. Optimal dosing, duration, and patient selection remain unclear. Whether benefits continue after stopping treatment is unknown. Head-to-head comparisons between peptides do not exist. Effects on different neuropathy subtypes, such as chemotherapy-induced or idiopathic, lack dedicated data. Long-term safety beyond short trial periods is unproven.

## Safety and limits

Reported side effects in human ARA290 and C-peptide trials stayed low with no major signals. Animal BPC-157 work shows no obvious toxicity at tested levels. Human experience overall remains small in scale. These compounds sit outside routine approved use for neuropathy in most regions. Any consideration requires medical oversight and awareness that evidence grades range from small human trials to animal models only.

## Claims (4)

- **c1** [human w=0.8] Long-acting C-peptide improved vibration perception threshold by 25% versus placebo in a 52-week RCT of 250 type 1 diabetes patients with neuropathy, but did not improve nerve conduction velocity or clinical scores.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [human w=0.8] ARA290 increased corneal small nerve fiber density and reduced neuropathic symptom scores in placebo-controlled trials of patients with sarcoidosis-associated small fiber neuropathy.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c3** [preclinical w=0.5] BPC-157 promoted axon regeneration and functional recovery after sciatic nerve transection in rat models.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c4** [anecdotal w=0.3] Reddit users report variable symptom relief with ARA290, including reduced burning and allodynia in some cases alongside occasional flares.
  - who_claims: grok/grok-4.3
  - sources: s4

## Voxel graph (4 atoms · 8 edges)
- full graph: https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (4)
- chain valid: yes · head: `9aeb19dfe2f2e8c9`

### s1 · pubmed · ok
- title: Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes
- url: https://pubmed.ncbi.nlm.nih.gov/26884473/
- summary: 52-week RCT details on C-peptide effects in diabetic neuropathy.
- quote: After 52 weeks, ... VPT had improved by 25% after 52 weeks of C-peptide therapy ... but resulted in marked improvement of VPT compared with placebo.
- claim_ids: c1
- hash: `357b6ac77132eb3b`

### s2 · pubmed · ok
- title: Targeting the innate repair receptor to treat neuropathy
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/
- summary: Human trial summaries on ARA290 for small fiber neuropathy.
- quote: ARA290 treatment over 28 days increased corneal small nerve fiber density ... In patients with sarcoidosis, ARA290 significantly improved neuropathic and autonomic symptoms.
- claim_ids: c2
- hash: `faae3246c0170a57`

### s3 · pubmed · ok
- title: Stable gastric pentadecapeptide BPC 157 can improve ...
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC6604284/
- summary: Rat studies on BPC-157 nerve and spinal repair.
- quote: BPC 157 ... therapeutic effects ... in spinal cord injury using a rat model. Spinal cord injury recovery was ...
- claim_ids: c3
- hash: `d3fe610e699cbdb1`

### s4 · reddit · ok
- title: Peptide ARA-290
- url: https://www.reddit.com/r/neuropathy/comments/1o33123/peptide_ara290/
- summary: Reddit discussion thread on ARA290 user experiences.
- quote: Has anyone tried the peptide ARA-290. It has clinical evidence of helping to slow or stop neuropathy and allow nerves to heal.
- claim_ids: c4
- hash: `9aeb19dfe2f2e8c9`

## Provenance (2 model passes)
- chain valid: yes · head: `513e243ee7eafe1c`

- write · grok/grok-4.3 · 2026-06-29T21:52 · hash `a95cee184303`
- voxel_divide · owner · 2026-07-17T02:43 · hash `513e243ee7ea`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"what-are-peptides-neuropathy","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest what-are-peptides-neuropathy|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim what-are-peptides-neuropathy|tier|assertion`
- **iMessage ask:** `what-are-peptides-neuropathy|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `what-are-peptides-neuropathy`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/what-are-peptides-neuropathy/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*